Biomea Fusion (BMEA) Q1 2026 earnings summary

Executive summary

• Focused on developing novel small molecule therapies for diabetes and obesity, with lead candidate icovamenib in Phase II trials for type 2 diabetes and recently completed Phase II trial for type 1 diabetes.

• Chronic toxicology studies for icovamenib completed, supporting chronic clinical dosing beyond 12 weeks in diabetes trials.

• Topline 52-week data from Phase II COVALENT-112 trial in type 1 diabetes showed sustained C-peptide preservation and favorable safety profile.

• BMF-650, a next-generation oral GLP-1 receptor agonist, is in Phase I for obesity, with data expected in Q2 2026.

• No products approved or revenue generated to date; company remains in clinical-stage development.

Financial highlights

• Net loss for Q1 2026 was $12.4 million, a significant improvement from $29.3 million in Q1 2025.

• Research and development expenses decreased to $9.1 million from $22.9 million year-over-year, mainly due to lower clinical and preclinical activity and reduced headcount.

• General and administrative expenses fell to $3.7 million from $6.8 million year-over-year, reflecting reduced headcount and corporate expenses.

• Cash, cash equivalents, and restricted cash totaled $45.1 million as of March 31, 2026.

• Accumulated deficit reached $461.5 million as of March 31, 2026.

Outlook and guidance

• Current cash resources are expected to fund operations into Q1 2027; additional capital will be required to continue as a going concern.

• Topline data from ongoing T2D Phase II trials expected in Q4 2026.

• Initial obesity trial data anticipated in Q2 2026.

• Plans to seek additional funding through equity, debt, or partnerships.

• Planned Phase II trial in recently diagnosed T1D patients to start in the second half of 2026.